Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company

Rhea-AI Summary

Genpact (NYSE: G) has been supporting embecta (Nasdaq: EMBC), a global diabetes care company, in its spin-off from Becton Dickinson and Company (BD) and its evolution as an independent leader in the diabetes technology market. Genpact's expertise in life sciences, healthcare, data, technology, and AI has enabled them to provide tailored solutions for embecta's needs.

The partnership has focused on modernizing embecta's operations, including implementing a robust ERP system, launching a standardized global operating model, and establishing end-to-end HR, finance, and procurement processes. This support has ensured uninterrupted customer service and supply chain stability, allowing embecta to continue providing insulin injection devices to 30 million people in over 100 countries.

Positive

• Successful spin-off of embecta from BD, establishing it as an independent company
• Implementation of robust ERP system and standardized global processes
• Uninterrupted customer support and supply chain stability maintained
• Continuous provision of insulin injection devices to 30 million people in over 100 countries

Negative

• None.

Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector

NEW YORK, July 29, 2024 /PRNewswire/ -- Genpact (NYSE: G), a global professional services and solutions firm delivering outcomes that shape the future, has been working with embecta (Nasdaq: EMBC), a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market.

"Genpact's deep expertise in the life sciences and healthcare sectors enables us to leverage extensive knowledge alongside our capabilities in data, technology, and AI. This combination allows us to drive positive outcomes and provide innovative solutions tailored to our clients' needs," said Balkrishan "BK" Kalra, President and CEO, Genpact. "Together, we are dedicated to realizing embecta's mission - to develop and provide solutions that make life better for people living with diabetes – and furthering Genpact's purpose: the relentless pursuit of a world that works better for people."

Genpact initially supported embecta's spin-off from BD and over time, the partnership has evolved to modernize embecta's operations. More specifically, Genpact supported the implementation of a robust ERP and launched an operating model with standardized global processes to meet the needs of a newly formed medical device company. Additionally, Genpact established end-to-end HR, finance, and procurement processes. This provided uninterrupted customer support and supply chain stability enabling embecta to continue providing insulin injection devices to 30 million people in more than 100 countries without interruption.

"From the beginning, our relationship was rooted in shared values and a commitment to mutual success," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer, embecta. "Our seamless collaboration resulted in the successful transition of embecta to an independent entity, ensuring a continuous flow of goods and working capital, maintaining supply chain continuity, and providing critical support for our customers and the people they serve."

Visit here for more information about Genpact's work in the healthcare industry.

About Genpact

Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose – the relentless pursuit of a world that works better for people – we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI.

Get to know us at genpact.com and on LinkedIn, X, YouTube, and Facebook. 

MEDIA CONTACT:

Siya Belliappa
Genpact Media Relations
+1 7185619843
Siya.belliappa@genpact.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-supports-embectas-spin-off-into-an-independent-diabetes-care-company-302208349.html

SOURCE Genpact Ltd.

FAQ

What support did Genpact provide for embecta's spin-off from BD?

Genpact supported embecta's spin-off by implementing a robust ERP system, launching a standardized global operating model, and establishing end-to-end HR, finance, and procurement processes. This ensured uninterrupted customer support and supply chain stability.

How many countries does embecta (EMBC) serve with its insulin injection devices?

embecta (EMBC) provides insulin injection devices to people in more than 100 countries.

What is the focus of Genpact's partnership with embecta (EMBC)?

Genpact's partnership with embecta (EMBC) focuses on modernizing operations, leveraging expertise in life sciences, healthcare, data, technology, and AI to provide tailored solutions that support embecta's mission of improving life for people with diabetes.

How many people use embecta's (EMBC) insulin injection devices?

embecta (EMBC) provides insulin injection devices to approximately 30 million people globally.